«King of probiotics» Bacillus coagulans in modern combined probiotic preparations Laktovit forte (full review)

Автор(и)

  • T Bomko Mechnikov Institute of Microbiology and Immunology,
  • A Martynov Mechnikov Institute of Microbiology and Immunology,
  • T Nosalska Mechnikov Institute of Microbiology and Immunology,
  • T Kabluchko Mechnikov Institute of Microbiology and Immunology,

Ключові слова:

Bacillus coagulans, pharmacology, biological properties, biological activity, bacteriocins, review

Анотація

Bacillus coagulans has an advantage over most other bacteria used as probiotics. It occupies an intermediate position between the genera Bacillusand Lactobacillus, is a spore-forming bacteria that produce lactic acid.This bacteria in the spores form can tolerate well technology processes, resistant to antibiotics and antiseptics, does not collapse under the influence of gastric juice and bile. Getting into the duodenum, the spores germinate into vegetative forms and begin vegetation and growth, providing probiotic effects. Bacillus coagulansrefers to semi-residental bacteria - performing in the human probiotic function, it passes the sporulation phase and slowly leaves the body, standing out in the faeces in the spores form. Thus, it does not violate the personal composition of intestinal microflora.Probiotic Bacillus coagulans enhances the microbiological composition of the intestine, increasing the number of obligate microorganisms and displacing pathogenic flora. Mechanisms of this action based on the lactic acid production and some bacteriocins synthesis, also on the immunomodulatory effect - stimulation of cellular and humoral immunity. The bacterial cell wall and spores are the main immunomodulatory compounds of the Bacillus coagulans.Apparently, namely Bacillus coagulans immunomodulatory properties play a crucial role in the pharmacological effects. It is now well known about the important role of immune system in the pathogenesis of many diseases; it has the clinical effect without the need for intensive growth of bacteria and intestinal colonization; even small amounts of spores are sufficient for pharmacological effect; many experimental evidences of the spore penetration into the lymphatic system and interaction with immunocompetent cells, as well as local and systemic immune effects of probiotic.In addition to this main action, Bacillus coagulans helps to digest lactose, possesses anti-inflammatory and antioxidant activity, as well as the cholesterol-lowering effect.The effectiveness of probiotics, containing spores of Bacillus coagulans, was confirmed by evidence-based medicine. Probiotic effect in the treatment of various diarrheas, including those related to antibiotic treatment, enterocolitis and irritable bowel syndrome. Bacillus coagulans application reduces the duration of diarrhea, reduces the severity of abdominal pain, and normalizes the composition of intestinal microflora.Bacillus coagulans efficiency is identified also as hypocholesterolemic agents, as a means of anti-inflammatory effect in the combination therapy of arthritis, in combination with soya extracts for reducing menopause symptoms; by topical application it was effective in vaginitis, stomatitis and dental caries. In clinical studies proved the high safety of probiotics. Except spores Bacillus coagulans, as part of the “Laktovit Forte” there are also present B9 and B12 vitamins in high doses, which are an essential component for the early spore’s vegetation in the large intestine. These vitamins stimulation phenomenon vegetation dispute has been confirmed experimentally, as shown in the clinic acceleration by 1-2 days of initial clinical manifestations of the effects of Bacillus coagulans, which is quite critical in acute diarrhea microbial origin, abdominal pain and cramps.

Посилання

Casula G. Bacillus probiotics: spore germination in

the gastrointestinal tract [Text] / G. Casula , S. M. Cutting

// Appl Environ Microbiol.- 2002.- Vol.68, N 5.-

P.2344-2352.

Adami, A. Biomass production, preservation and

characteristics of a strain of Bacillus coagulans as probiotic[

Text]/ A.Adami, V. Cavazzoni // Microbiologie

Aliments Nutrition.-1993.- Vol. 11.- P. 93-100.

Snetah P H A, Mair N S, Sharpe M E, Holt J G

(EDS). Genus Bacillus Cohn 1872. [Text] // Bergey’s

Manual of Systematic Bacteriology (Baltimore: Williams

and Wilkins).- 1986.-1105 - Claus D, Berkeley R C W 39

Claus, D. and Berkeley, R.C.W. (1986). Genus

Bacillus Cohn 1872. In Snetah, P.H.A., Mair, N.S.,

Sharpe, M.E. and Holt, J.G. (EDS), Bergey’s Manual of

Systematic Bacteriology (Baltimore: Williams and Wilkins)

[Text] // pp.1105-1139.

FAO/WHO. Expert Consultation on Evaluation of

Health and Nutritional Properties of Probiotics in Food

including Powder Milk with Live Lactic Acid Bacteria

[Text] // Report 2001. FAO/WHO; Сordoba, Argentina:

Nakamura L K. Phylogeny of Bacillus sphaericus –

like organisms [Text]/ L. K. Nakamura // International

Journal of Systemic and Evolutionary Microbiology.-

-Vol.50.-P.1715-1722.

EverPup. Режим доступа:

http://www.everpup.co.uk/ingredients/probiotics-fromlactobacillus-

sporogenes/

Weese J.S. Microbiologic evaluation of commercial

products [Text]/ J. S. Weese // Journal of the American

Veterinary Medical Association.- 2002.-Vol. 220.- P.

-797.

De Vecchi E. Lactobacillus sporogenes or Bacillus

coagulans: misidentification or mislabelling? [Text]/ E.

De Vecchi, L. Drago //International Journal of Probiotics

and Prebiotics.- 2006.- Vol.1, N.1.- P.3-10.

Pat. US8697055 B2 US, Probiotic, lactic acidproducing

bacteria / Farmer Sean (Miami, FL); FARMER

SEAN [US]; GANEDEN BIOTECH INC [US]. – US

/423,852; Filed: March 19, 2012; Date of Patent Apr.

, 2014.

Abdhul K. Bacteriocinogenic potential of a probiotic

strain Bacillus coagulans [BDU3] from Ngari [Text] /

Abdhul K., M. Ganesh, S. Shanmughapriya, et al.//

IntJBiolMacromol.- 2015.-Vol. 79.-P.: 800-806.

Hyronimus B. Acid and bile tolerance of sporeforming

lactic acid bacteria [Text] / B. Hyronimus, C. Le

Marrec, A. H. Sassi, A. Deschamps // International Journal

of Food Microbiology.- 2000.-Vol.61, N 1-2.-P.193-

Lactobacillus sporogenes improves gastrointestinal

ecology // Alternative Medicine Review, August, 2002.

Режим доступа: http://forums.prohealth.com/ forums/

index.php?threads/ lactobacillus-sporogenesimproves-

gastrointestinal-ecology.131865/

Chateau N.Heterogeneity of bile salts resistance in

the Lactobacillus isolates of a probiotic consortium [Text]

/ N.Chateau, A.M. Deschamps, A. Hadj Sassi // Letts

Appl Microbiol.-1994.-Vol.18.-P.42–44.

Jacobsen C.N.Screening of probiotic activities of

forty-seven strains of Lactobacillus spp. by in vitro techniques

and evaluation of the colonization ability of five

selected strains in humans [Text] / C.N.Jacob-sen, Rosenfeldt

Nielsen V., A.E. Hayford, et al. // Appl Environ

Microbiol.-1999.-Vol. 65.-P. 4949–4956.

Zarate G.Effect of bile on the β-galactosidase activity

of dairy propionibacteria [Text]/G. Zarate, S. Gonzalez,

A.P. Chaia, G. Oliver // Lait.-2000.-Vol.80.- P.267–

Ibrahim S.A. Survival of bifidobacteria in the presence

of bile salt [Text]/ S.A.Ibrahim, A. Bezhorovainy // J

Sci Food Agric.-1993.-Vol. 62.-P.351–354.

Clark P.A., Martin J.H. Selection of bifidobacteria

for use as dietary adjuncts in cultured dairy foods. III.

Tolerance to simulated bile concentrations of human

small intestines[Text]/ P.A.Clark, J.H. Martin // Cult

Dairy Prod J.-1994.-Vol.29.- P.18–21.

Hong H. A. The use of bacterial spore formers as

probiotics [Text]/H. A. Hong, L.H. Duc, S. M.Cutting //

FEMS Microbiology Reviews.- 2005.- Vol.29, N.4.-

P.813-835.

Amaha M., Ordal Z.J., Touba A. Sporulation requirements

of Bacillus coagulans var. Thermoacidurans in

complex media / M. Amaha, Z.J.Ordal, A. Touba // J

Bacteriol.- 1956.- Vol.72, N1.- P.34–41.

Palestrant D. Microbial biofilms in the gut: visulalization

by electron microscopy and by acridine orange

staining [Text] / D. Palestrant, Z. E. Holzknecht, B.

H. Collins, et al. // Ultrastruct Pathol.-2004.-Vol.28.-

Р.23–27.

Mendelson N.H. Bacillus subtilis macrofibres, colonies

and bioconvection patterns use different strategies

to achieve multicellular organization [Text] / N.H. Mendelson

// Environ Micribiol.-1999. .-Vol.1.-P.471–477.

Rajagopalan S. Modeling substrate particle degradation

by Bacillus coagulans biofilm [Text] / S. Rajagopalan,

D. A. Rockstraw, S. Munson-McGee // Bioresource

Technol.-1997 .-Vol.61, N.3.-P.175-183

Quintelas C. Biosorption of Cr(VI) by a Bacillus

coagulans biofilm supported on granular activated carbon

(GAC) [Text]/ C. Quintelas, B. D. Fernandes, J. Castro, et

al. // Chemical Engineering Journal.- 2008 .-Vol.136, N

-3.-P.195-203.

Duc L.H.Bacterial spores as vaccine vehicles

[Text]/L.H. Duc, H.A. Hong, N.Fairweather, et al. // Infect

Immunol.- 2003 .-Vol.71.-P.2810–2818.

Hoa T.T. Fate and dissemination of Bacillus subtilis

spores in a murine model [Text] / T.T. Hoa, L.H. Duc, R.

Isticato, et al. // Appl Environ Microbiol.-2001 .-Vol. 67.-

N 9.- P.3819-3823.

Smirnov V.V. The effect of the complex probiotic

Sporolact on the intestinal microbiocenosis of warmblooded

animals [Text] / V.V. Smirnov, S.R. Reznik,

V.A. V'iunitskaia, et al. // MikrobiolZ.-1995.- Vol.57.-

P.42-49.

Adami A. Occurrence of selected bacteria groups in

the faeces of piglets fed with Bacillus coagulans as probiotic

[Text]/A. Adami, V. Cavazzoni // J Basic Microbiol.-

-Vol.39.-P.3-9.

Donskey C.J. Effect of oral Bacillus coagulans

administration on the density of vancomycin-resistant

enterococci in the stool of colonized mice [Text] /C.J.

Donskey, C.K. Hoyen, S.M. Das, et al. // Letters in Applied

Microbiology.-2001.-Vol.33.-P. 84-88.

Hyronimus B. Coagulin, a bacteriocin - like inhibitory

substance produced by Bacillus coagulans I4 [Text] /

B. Hyronimus, C. Le Marrec, M.C. Urdaci // J Appl Microbiol.-

-Vol.-85, N 1.- P.42-50.

Le Marrec C. Biochemical and genetic characterization

of coagulin, a new antilisterial bacteriocin in the

pediocin family of bacteriocins, produced by Bacillus

coagulans I(4) [Text] / C. Le Marrec, B. Hyronimus, P.

Bressollier et al. // Appl Environ Microbiol.- 2000 .-Vol.-

,N 12 .- P.5213-5220.

Riazi S. Mode of action and safety of lactosporin, a

novel antimicrobial protein produced by Bacillus coagulans

ATCC 7050 [Text] S. Riazi, S. E. Dover, M. L.

Chikindas. // J Appl Microbiol.- 2012.-Vol. 113, N 3.-

P.714-722.

Riazi S. Characterization of lactosporin, a novel

antimicrobial protein produced by Bacillus coagulans

ATCC 7050.[Text] / Riazi S., R. E. Wirawan, V.

Badmaev, et al.// J Appl Microbiol.- 2009.-Vol. 106, N 4.-

P.1370-1377.

Czaczyk K. Antifungal activity of Bacillus coagulans

against Fusarium sp. [Text] / K. Czaczyk, K. Trojanowska,

A. Mueller. // Acta Microbiol Pol.- 2002.-Vol. 51,

N 3 - P.275-283.

Lin S.Y. Effects of supplement with different level

of Bacillus coagulans as probiotics on growth performance

and intestinal microflora populations of broiler

chickens [Text]/ S.Y. Lin, A.T.Y. Hung, J.J. Lu // Journal

of Animal and Veterinary Advances.- 2011.-Vol. 10, N

- P.111-114

. Nyangale E.P. Bacillus coagulans GBI-30, 6086

Modulates Faecalibacterium prausnitzii in Older Men and

Women [Text] / E.P. Nyangale, S. Farmer, H.A. Cash et

al. // J Nutr.- 2015 .-Vol.-145, N 7.-P.1446-1452.

Drago L. Should Lactobacillus sporogenes and

Bacillus coagulans have a future? [Text] / L.Drago,E. De

Vecchi. // J Chemother.- 2009.-Vol. 21,N 4 - P. 371-377.

Babar V. Immunomodulatory activity of Lactobacillus

sporogenes [Text] /V. Babar, R. Thomas, M.

Bhaskar // International Journal of Therapeutic Applications.-

.-Vol.3.- P.32–38.

Ostad S.N. Live and heat-inactivated lactobacilli

from feces inhibit Salmonella typhi and Escherichia coli

adherence to Caco-2 cells [Text] / S.N. Ostad, A.A. Salarian,

M.H. Ghahramani, et al. // Folia Microbiol (Praha).-

- Vol.54.- P.157-160.

Jensen G.S. Ganeden BC30 cell wall and metabolites:

anti-inflammatory and immune modulating effects

in vitro [Text] / G.S. Jensen, K.F. Benson, S.G. Carter,

J.R. Endres // BMC Immunol.- 2010.- Vol.11, N. 15., P.1-

Mandel D.R.Bacillus coagulans: a viable adjunct

therapy for relieving symptoms of rheumatoid arthritis

according to a randomized, controlled trial BMC [Text] /

D.R. Mandel, K. Eichas, J. Holmes // Complementary and

Alternative Medicine.- 2010.-Vol.10.-P.1-12.

Fitzpatrick L.R. Probiotics for the treatment of

Clostridium difficile associated disease [Text] / L.R Fitzpatrick

//World J Gastrointest Pathophysiol.-2013 .-

Vol.4,N 3.- P.47-52.

Surawicz C.M. The search for a better treatment for

recurrent Clostridium difficile disease: use of high-dose

vancomycin combined with Saccharomyces boulardii

[Text] / C.M. Surawicz, L.V. McFarland, R.N. Greenberg,

et al. // Clin Infect Dis.- 2000.-Vol.31.-P.1012–

Fitzpatrick L.R. Bacillus Coagulans GBI-30

(BC30) improves indices of Clostridium difficile-Induced

colitis in mice [Text] / L.R. Fitzpatrick, J.S. Small, W.H.

Greene, et al.// Gut Pathogens.-2011.-Vol.3.-P.16-19.

Flahaut S. Comparison of bile salts and sodium

doceyl sulfate stress responses in Enterococcus faecalis

[Text] / S. Flahaut, J. Frere, P. Boutibonnes, Y. Auffray //

Appl Environ Microbiol.-1996.-Vol. 62.-P.2416–2420.

Fitzpatrick L.R. Bacillus coagulans GBI-30, 6086

limits the recurrence of Clostridium difficile-Induced

colitis following vancomycin withdrawal in mice/ L.R.

Fitzpatrick, J.S. Small, W.H. Greene, et al. // Gut Pathog.-

-Vol. 4,N 1.- P.13-16.

Massot J. Bacterio-pharmacological activity of

Saccharomyces boulardii in clindamycin-induced colitis

in the hamster [Text] / J. Massot, O. Sanchez, R. Couchy,

J. Astoin, A.L. Parodi // Arzneimittelforschung.-1984.-

Vol.34.-P.794–797

Toothaker R.D. Prevention of clindamycin-induced

mortality in hamsters by Saccharomyces boulardii [Text]

/ R.D. Toothaker, G.W. Elmer // Antimicrob Agents

Chemother.- 1984.-Vol. 26.-P.552–556.

Corthier G. Prevention of Clostridium difficile

induced mortality in gnotobiotic mice by Saccharomyces

boulardii [Text] / G. Corthier, F. Dubos, R. Ducluzeau //

Can J Microbiol.- 1986. -Vol.32.-P.894–896.

Martins F.S. Screening of yeasts as probiotic based

on capacities to colonize the gastrointestinal tract and to

protect against enteropathogen challenge in mice [Text] /

F.S. Martins, R.M. Nardi, R.M. Arantes et al. //J Gen

Appl Microbiol.- 2005. -Vol.51.- P.83–92.

Naaber P. Bacterial translocation, intestinal microflora

and morphological changes of intestinal mucosa in

experimental models of Clostridium difficile infection

[Text] / P. Naaber, R.H. Mikelsaar, S. Salminen, M.

Mikelsaar // J Med Microbiol.-1998 -Vol.47.- P.591–598.

Kaur S. Effect of Lactobacillus acidophilus & amp;

epidermal growth factor on experimentally induced Clostridium

difficile infection [Text] / Kaur S., C. Vaishnavi,

K.K. Prasad, et al. // Indian J Med Res.- 2011 -Vol.133.-

P.434–441.

Pillai A. Probiotics for treatment of Clostridium

difficile-associated colitis in adults [Text] /A. Pillai, R.

Nelson // Cochrane Database Syst Rev.- 2008.-

Vol.23:CD004611.

Baron M. Apatented strain of Bacillus coagulans

increased immune response to viral challenge / M. Baron

// Postgrad Med.-2009. -Vol.121.- P.114-118.

Kimmel M. A controlled clinical trial to evaluate

the effect of Ganeden BC30 on immunological markers

[Text]/ M. Kimmel, D. Keller, S. Farmer, D. E. Warrino //

Methods and Findings in Experimental Clinical Pharmacology.-

-Vol.32.- P.129-132.

Lactospore. Режим доступа:

http://www.lactospore.com/about/background-info/

Kodali V.P. Antioxidant and free radical scavenging

activities of an exopolysaccharide from a probiotic bacterium/

V.P. Kodali, R. Sen // Biotechnol J.- 2008.-Vol.3.-

P. 245-251.

Solanki H.K. Evaluation of anti-inflammatory activity

of probiotic on carrageenan-induced paw edema in Wistar

rats [Text]/ H.K. Solanki // Int J Biol Macromol.- 2015 -

Vol.72.- P.1277-1282.

Kumar O.R.M. Feeding of L. sporogenes to rabbits/

O.R.M. Kumar, K.J. Christopher // Ind. Vet. J.- 1989. -

Vol.66.- P.896-898.

Mohan J.C. Short term hypolipidemic effects of oral

Lactobacillus sporogenes therapy in patients with primary

dyslipidemias [Text] / J.C. Mohan, R. Arora, M. Khalilullah

// Indian Heart Journal.- 1990. -Vol.42.- P.361-

Kashyap D. R. Enhanced production of pectinase by

Bacillus sp. DT7 using solid state fermentation [Text] / D.

R.Kashyap, S. K. Soni,R. Tewari // Bioresour Technol.-

-Vol. 88,N. 3.- P.251-254.

Campbell L. L. Folic acid requirement of Bacillus

coagulans[Text] / L. L.Campbell,E. E. Sniff. // J Bacteriol.-

-Vol. 78.- P.267-271.

Marshall R. Growth of Bacillus coagulans in chemically

defined media [Text] / R.Marshall,R. J. Beers. // J

Bacteriol.- 1967.-Vol. 94,N.3.-P. 517-521.

Stover P.I. Physiology of folate and vitamin B12 in

health and disease / P.I. Stover // Nutr Bcv.-2004. -Vol.

(Pt 2).- P.53-55.

Troen A.M. Un metabolized folic acid in plasma is

associated with reduced natural killer cell cytotoxicity

among postmenopausal women [Text] / A.M. Troen, B.

Mitchell, B. Sorensen, el al. // J. Nutr.-2006.-Vol. 1361.-

P.189-94.

Yamaguchi T. Control of immune responses by

antigen-specific regulatory T cells expressing the folate

receptor/T. Yamaguchi, K.Hirota, K. Nagahama, et al.//

Immunity.-2007. -Vol. 271.- P.145-159.

Kunisawa E.A pivotal role of vitamin B9 in the

maintenance of regulatory T cells in vitro and in vivo

[Electronic source] / E.Kunisawa, E. Hashimoto,

I.Ishikawa, H.Kiyono // PLoS ONE.- 2012.-

Vol.72:e32094. doi:l0.137l/journal.pone.0032094

Kinoshita M.Dietary folic acid promotes survival of

Foxp3T regulatory T cells in the colon [Text] /

M.Kinoshita, H.Kayama, T. Kusu et al. // Immunol.-2012.

-Vol.1896.-P.2869-2878.

Le Bourhis L.Mucosal-associated invariant T cells:

unconventional development and function [Text]/L.Le

Bourhis, L. Guerri, M.Dusseaux, et al. // Trends Immunol.-

-Vol.325.-P.212-218.

Kjer-Nielsen L. MRl presents microbial vitamin B

metabolites to MAIT cells [Electronic source]/L. Kjer-

Nielsen, O.Patel, A.I. Corbett, et al. // Nature.-2012.-Vol.

-P. 717-723. doi:l0.1038/natureI1605

La Rosa M. Prevention of antibiotic-associated

diarrhoea with Lactobacillus sporogenes and fructooligosaccharides

in children. A multicenter double-blind

vs. placebo study [Text] / M. La Rosa, G. Bottaro, N.

Gulino et al.// Minerva Pediatrica.-2003.-Vol.55.- P.447-

Majeed M. Bacillus coagulans – probiotic of choice

[Text] / M. Majeed, R. Kamarei // Prebiotics/Probiotics.-

- P.19-21.

Abstracts of papers on the clinical study of Sporlac,

complied by the Sankyo Co., Ltd. Japan

Chandra R. K. Effect of Lactobacillus on the incidence

and severity of acute rotavirus diarrhoea in infants.

A prospective placebo-controlled double-blind study

[Text] / R.K. Chandra // Nutritional Research.-2002.-

Vol.22, N 1.- P.65-69.

Dutta P. Randomised controlled clinical trial of

Lactobacillus sporogenes (Bacillus coagulans), used as

probiotic in clinical practice, on acute watery diarrhoea in

children [Text]/ P. Dutta, U. Mitra, S. Dutta, et al. //

Tropical Medicine and International Health.- 2011.-

Vol.16, N 5.- P.555-561.

Sari F.N. Oral probiotics: Lactobacillus sporogenes

for prevention of necrotizing enterocolitis in very lowbirth

weight infants: a randomized, controlled trial [Text]/

F.N. Sari, E.A. Dizdar, S. Oguz, et al. //European Journal

of Clinical Nutrition. – 2011. – Т. 65. – №. 4. – С.434-

Cui Y.L.Efficacy of Bacillus coagulans tablets in

the treatment of acute and chronic diarrhea [Text] / Y.L.

Cui, F.C. Wan, D.L. Tang, S.H.Wu // Int J Immunotherapy.-

- Vol.20, N 1.- P.17-22.

Hun L. Bacillus coagulans significantly improved

abdominal pain and bloating in patients with IBS [Text]/

L. Hun // Postgrad Med.-2009.- Vol.121.- P. 119-24

Dolin B.J. Effects of a proprietary Bacillus coagulans

preparation on symptoms of diarrhea-predominant

irritable bowel syndrome/ B. J. Dolin // Methods Find

Exp Clin Pharmacol.- 2009.- Vol.31, N 10.-P.655-659

Rogha M. The efficacy of a symbiotic containing

Bacillus Coagulans in treatment of irritable bowel syndrome:

a randomized placebo-controlled trial [Text] / M.

Rogha, M. Z. Esfahani,A. H. Zargarzadeh// Gastroenterology

and hepatology from bed to bench.- 2014.-Vol.7,

N3- P.-156-163.

Keller D. Bacillus coagulans as a probiotic [Text]/

D. Keller, S. Farmer, A. McCartney, G. Gibson // Food

Science and Technology Bulletin: Functional Foods.-

- Vol.7, N 7.- P.103–109.

Mohan J.C. Preliminary observations on effect of

Lactobacillus sporogenes on serum lipid levels in hypercholesterolemic

patients [Text]/ J.C. Mohan, R. Arora,

M. Khalilullah // Indian Journal of Medical Research.-

-Vol.92.- P.431-432

Agosta C., Atlante M., Benvenuti C. Randomized

controlled study on clinical efficacy of isoflavones plus

Lactobacillus sporogenes, associated or not with a natural

anxiolytic agent in menopause/ C. Agosta, M. Atlante, C.

Benvenuti // Minerva Ginecol.- 2011.- Vol.63, N 1.- P.11-

Benvenuti C., Setnikar I. Effect of Lactobacillus

sporogenes on oral isoflavones bioavailability: single dose

pharmacokinetic study in menopausal women [Text] / C.

Benvenuti, I. Setnikar // Arzneimittel-forschung.-2011.-

Vol.61, N 11.- P.605-609

Palacios S. Women's perception of the efficacy of a

soy extract with probiotic: the M3 study [Text] /

S.Palacios, I. A. Rojo, M. J. Cancelo, et al. // Gynecol

Endocrinol.- 2008.-Vol. 24, N4.– P.-178-183

Voichishina L.G. The use of sporulating bacteria in

treating patients with dysbacteriosis [Text] / L.G.

Voichishina, V.A. Chaplinskii, V.A.V'iunitskaia // Vrach

Delo- 1991.- Vol.12.- P. 73-75.

Mathur S.N. Sporlac therapy in treatment of aphthous

stomatitis [Text] / S.N. Mathur // Uttar Pradesh

State Dent J.- 1970.-Vol. 11.- P. 7-12.

Sharma J.K. Clinical trial of Sporlac in the treatment

of recurrent aphthous ulceration [Text] / J.K. Sharma,

K.K. Kapoor, R.D. Mukhija // Uttar Pradesh State

Dent J.- 1980.-Vol.11.- P.7-12.

Jindal G. A comparative evaluation of probiotics on

salivary mutans streptococci counts in Indian children

[Text] / G. Jindal, R.K. Pandey, J. Agarwal, M. Singh //

Eur Arch Paediatr Dent.- 2011.-Vol. 12.- P.211-215.

Shirodkar N.V. Multi-centre clinical assessment of

Myconip vaginal tablets in non-specific vaginitis [Text] /

N.V. Shirodkar, P.C. Sankholkar, S. Ghosh, S.M. Nulkar

// Indian Pract.- 1980.-Vol.33.- P.207-210.

Sanders M.E. Sporeformers as Human Probiotics:

Bacillus, Sporolactobacillus, and Brevibacillus [Text] /

M.E. Sanders, L. Morelli, T.A. Tompkins // Comprehensive

Reviews in Food Science and Food Safety.- 2003.-

Vol.2, N.3.- P.101

Mandel D.R., Eichas K., Holmes J. Bacillus coagulans:

a viable adjunct therapy for relieving symptoms of

rheumatoid arthritis according to a randomized, controlled

trial [Text] / D.R. Mandel, K. Eichas, J. Holmes // BMC

Complement Altern Aferf.-2010.-Vol.10.- P. l.

Endres, J. R. Safety assessment of a proprietarypreparation

of a novel probiotic, Bacillus coagulans,

as a food ingredient [Text] / J. R.Endres, A.Clewell, K.

A.Jade, et al.// Food Chemistry and Toxicology.-2009. -

Vol. 47, N 6.-P.1231- 1238.

Abhari Kh.The effects of probiotic, prebiotic and

synbiotic diets containing Bacillus coagulans and inulin

on rat intestinal microbiota [Text] / Abhari Kh., Shekarforoush

S.S., Sajedianfard J., Hosseinzadeh S., Nazifi S. //

IJVR. – 2015. – 16, N3. – Р. 267-273.

Gu Sh.B. Potential probiotic attributes of a new

strain of Bacillus coagulans CGMCC 9951 isolated from

healthy piglet feces [Text] / Sh.B.Gu, L.N.Zhao, Y.Wu, et

al.// World J. Microbiol. Biotechnol. – 2015. – 31, N6. –

Р.851-863.

Ratna Sudha M. Clinical Study of Bacillus coagulans

Unique IS-2 (ATCC PTA-11748) in the Treatment of

Patients with Bacterial Vaginosis [Text] / M.Ratna Sudha,

K.A.Yelikar, S. Deshpande // Indian J Microbiol. – 2012.

– 52, N3. – Р.396-399.

Dutta Ph.Randomised controlled clinical trial of

Lactobacillus sporogenes(Bacillus coagulans), used as

probiotic in clinical practice, on acute watery diarrhoea in

children [Text] / Dutta Ph., Mitra U., Dutta Sh., et al. //

Trop. Med. Int. Health. – 2011. – 16, N5. – Р.555-561.

Cano Roca C.L. Characterization of Commercial

Probiotics: Antibiotic Resistance, Acid and Bile Resistance,

and Prebiotic Utilization [Text] / C.L. Cano

Roca // Dissertations & Theses in Food Science and

Technology. – 2014. – 46 р.

Spinosa M.R.The trouble in tracing opportunistic

pathogens: cholangitis due to Bacillus in a French hospital

caused by a strain related to an Italian probiotic? [Text] /

M.R.Spinosa, F.Wallet, R.J.Courcol, M.R. Oggioni //

Microbial Ecology in Health and Disease. – 2000. – Vol.

– Р.99-101.

De Clerck E. Genotypic diversity among Bacillus

licheniformis strains from various sources [Text] / E.De

Clerck, P.De Vos // FEMS Microbiol Lett. – 2004. – Vol.

– Р.91-98.

Attachment I final risk assessment of Bacillus licheniformis

// Режим доступа:

http://www.epa.gov/sites/production/files/2015-

/documents/fra005.pdf. - 1997.

Glushanova N.A. Biological properties of lactobacilles

[Text] /N.A. Glushanova // Bull.sib med – 2003. –

N4. – P.50-58.

##submission.downloads##

Як цитувати

Bomko, T., Martynov, A., Nosalska, T., & Kabluchko, T. (2020). «King of probiotics» Bacillus coagulans in modern combined probiotic preparations Laktovit forte (full review). Анали Мечниковського Інституту, (1), 17–37. вилучено із https://journals.uran.ua/ami/article/view/190915

Номер

Розділ

Дослідні статті